Global Gabapentin Market - 2023-2030

Global Gabapentin Market - 2023-2030

Global gabapentin market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Gabapentin is a medication primarily used to treat different neurological conditions. Its most common application is for managing neuropathic pain and epilepsy. This anticonvulsant and analgesic drug works by modulating the activity of specific neurotransmitters in the brain, which helps to reduce pain signals in the nervous system.

Gabapentin is an effective treatment for these conditions, and it has become a widely prescribed and researched drug, providing hope and relief to countless individuals worldwide.

Market Dynamics: Drivers and Restraints

Increasing usage of gabapentin as a pain management solution is expected to drive the market growth

Gabapentin has become increasingly popular as a pain management solution because of its effectiveness in treating neuropathic pain. This type of pain arises from damage or abnormal activity in the peripheral nervous system and is often chronic and debilitating. Conditions like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia can cause neuropathic pain. Gabapentin works by modulating the activity of specific neurotransmitters in the nervous system, which reduces the transmission of pain signals and helps alleviate the pain.

Neuropathic pain affects tens of millions of people worldwide, and the demand for gabapentin has increased as a result. Healthcare professionals often prefer gabapentin due to its efficacy in treating neuropathic pain.

For instance, according to an article published in Cureus in 2022, neuropathic pain affects approximately 3-17% of the general population. It is characterized by both positive and negative aspects, where positive aspects include extra sensations like pain, paresthesia, numbness, and tingling, and negative aspects include loss of functions such as sensory, motor, and cognitive deficits. Neuropathy can be a component of chronic pain and may be part of mixed pain syndromes. Conventional analgesics that are used to treat nociceptive pain may not be effective in treating neuropathic pain.

Therefore, the demand for a safer and more efficient solution for neuropathic pain has driven the market growth of gabapentin, positioning it as a valuable therapeutic option for individuals seeking relief from this challenging and prevalent condition.

Furthermore, the high prevalence of neurological disorders, availability and low cost of generic drugs, and growing awareness among patients about gabapentin's effectiveness are the factors expected to drive the market over the forecast period.

Restraint:

Side effects and tolerance, alternative therapies, generic competition, and an emerging threat due to its potential for misuse and abuse are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global gabapentin market is segmented based on type, dosage form, application, distribution channel and region.

The generic from the type segment accounted for approximately 56.4% of the gabapentin market share

Gabapentin generics, or generic gabapentin, are formulations of gabapentin produced by various manufacturers that are not protected by patents. These generic versions offer many advantages, including greater affordability compared to brand-name versions, which allows for a broader population of patients to access this important medication. Generic gabapentin contains the same active ingredient as the brand-name version, ensuring similar efficacy in treating conditions such as neuropathic pain and epilepsy.

Moreover, the availability of generic gabapentin not only reduces healthcare costs but also increases competition in the pharmaceutical market. This competition can drive innovation and further research in the development of medications based on gabapentin, which can benefit patients who need effective pain management and neurological disorder treatment.

For instance, in February 2023, Zydus Lifesciences received approval from the U.S. health regulator to market generic medicines in the American market. The company has received approval from the U.S. Food and Drug Administration to market Gabapentin tablets which are indicated for the management of postherpetic neuralgia.

Similarly, on September 18, 2023, Lotus Pharmaceutical, a leading global pharmaceutical company, partnered with the top B2B pharma player, Adalvo, to launch Gabapentin ER 300/600 mg in South Korea. This 505b(2) product is derived from the reference brand Neurontin Hard Capsule 300mg and Neurontin Film Coated Tablet 600mg. It is designed to provide long-lasting relief to individuals suffering from Postherpetic Neuralgia (PHN), a debilitating condition that can significantly reduce one's quality of life. With its once-daily dosing regimen, Gabapentin ER offers a more convenient treatment option for patients, resulting in a meaningful improvement in their quality of life.

Geographical Analysis

North America accounted for approximately 44.2% of the market share in 2022

North America is expected to hold the largest market share, owing to the high incidence of neurological disorders, increasing product launches, and presence of key players in the region.

For instance, the Alzheimer's Association reports that 1 in 10 Americans over the age of 65 suffer from Alzheimer's. More than 5 million Americans are currently living with Alzheimer's, and it's estimated that by 2050, this number will increase to about 16 million. Therefore, gabapentin, which is effective in managing neuropathic pain, may become an increasingly popular therapeutic option for treating pain-related symptoms in Alzheimer's patients. As the number of individuals with Alzheimer's continues to grow, there is a greater need for safe and reliable pain management solutions like gabapentin, making it an essential component in the comprehensive care and treatment of this expanding patient population.

Additionally, on November 17, 2021, Camber Pharmaceuticals expanded its existing product lineup by launching Gabapentin Tablets, which offer the generic equivalent of Neurontin. These tablets are prescribed in conjunction with other medications to manage partial seizures in both adults and children aged three years and above. Camber's Gabapentin Tablets are available in two strengths, 600 mg, and 800 mg, and come in bottles of 100 and 500 tablets.

In contrast, there is a growing body of evidence indicating that gabapentin is being misused and leading to overdoses, often when combined with opioids. This is bringing attention to the issue of substantial off-label prescribing of the drug, which is primarily used as an anticonvulsant.

In addition, the FDA is now requiring new warnings for gabapentinoids regarding the risk of respiratory depression. Drug manufacturers are also required to conduct clinical trials to further investigate the abuse potential of gabapentinoids, especially when used in combination with opioids. Special attention is being given to assessing the respiratory depressant effects.

COVID-19 Impact Analysis

The gabapentin market was significantly impacted by the COVID-19 pandemic, with both positive and negative effects. On the positive side, there was a notable increase in demand for gabapentin as the pandemic highlighted the importance of effective pain management, especially for individuals experiencing heightened stress, anxiety, and pain due to the global health crisis. The drug's off-label use for anxiety and stress-related conditions experienced a surge in prescriptions.

The COVID-19 pandemic resulted in disruptions to the pharmaceutical supply chain, which caused shortages of certain medications such as gabapentin. This made it difficult for patients to access the medications they needed, while healthcare providers had to find ways to ensure a consistent supply. Additionally, the pandemic highlighted the potential for misuse and addiction to medications like gabapentin, leading regulatory bodies to implement tighter controls. Overall, the COVID-19 impact on the gabapentin market was characterized by increased demand, supply chain challenges, and greater scrutiny regarding its use.

Market Segmentation:

By Type
• Generic
• Branded

By Dosage Form
• Tablet
• Capsule
• Solution

By Application
• Neuropathic Pain
• Epilepsy
• Restless Leg Syndrome
• Anxiety
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the gabapentin market include Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma USA, Amneal Pharmaceuticals LLC, Pfizer Inc., and Cipla Inc. among others.

Key Development
• On February 20, 2023, Zydus Lifesciences Limited’s (including its subsidiaries/affiliates hereafter referred to as “Zydus”) subsidiary Zydus Pharmaceuticals (USA) Inc. received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg (USRLD: Gralise Tablets). Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN). The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
• On March 29, 2023, Granules India Ltd, a pharmaceutical company, granted approval by the US Food & Drug Administration (USFDA) for its generic gabapentin tablets. These tablets are used for the management of postherpetic neuralgia in adults. The approval is for the abbreviated new drug application (ANDA) for Gabapentin tablets with strengths of 600 mg and 800 mg.

Why Purchase the Report?
• To visualize the global gabapentin market segmentation based on type, dosage form, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of gabapentin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global gabapentin market report would provide approximately 69 tables, 68 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies